title: Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells.
abstract: Receptor EphA2 is overexpressed in lung cancer and malignant pleural mesothelioma (MPM) which promote tumorogenesis. Lipoplatin™, a new liposomal cisplatin formulation, is used against resistant tumors. Use of cisplatin-based drugs leads to unacceptable toxicities. To improve the effectiveness of Lipoplatin, enhancing the cellular sensitivity of lung tumor and MPM cells is critical. Therefore, we targeted receptor EphA2 by silencing interference RNA (siRNA) and treated tumor cells with Lipoplatin. The combined effects of siRNA-EphA2 and Lipoplatin were determined. We report that silencing EphA2 significantly enhanced the cellular sensitivity of lung tumor and MPM cells to Lipoplatin and maybe a potential therapy for lung cancer.
authors.affiliation: a Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine , University of Florida , Gainesville , FL , USA.|b Biomaterials Center, Department of Materials Sciences and Engineering , University of Florida , Gainesville , FL , USA.
authors.forename: Hung-Yen
authors.initials: HY
authors.lastname: Lee
authors.affiliation: a Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine , University of Florida , Gainesville , FL , USA.|c NF/SGVHS, Malcom Randall VA Medical Center , University of Florida , Gainesville , FL , USA.
authors.forename: Kamal A
authors.initials: KA
authors.lastname: Mohammed
authors.affiliation: b Biomaterials Center, Department of Materials Sciences and Engineering , University of Florida , Gainesville , FL , USA.
authors.forename: Eugene P
authors.initials: EP
authors.lastname: Goldberg
authors.affiliation: d Department of Hematology and Oncology , University of Florida , Gainesville , FL , USA.
authors.forename: Frederic
authors.initials: F
authors.lastname: Kaye
authors.affiliation: a Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine , University of Florida , Gainesville , FL , USA.|c NF/SGVHS, Malcom Randall VA Medical Center , University of Florida , Gainesville , FL , USA.
authors.forename: Nasreen
authors.initials: N
authors.lastname: Najmunnisa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D015415:Biomarkers; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics; D002945:Cisplatin / Q000494:pharmacology*; D053938:DNA Fragmentation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015870:Gene Expression; D020868:Gene Silencing; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism; D008654:Mesothelioma / Q000235:genetics* / Q000378:metabolism; D000086002:Mesothelioma, Malignant; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D036104:Receptor, EphA2 / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C503131:lipoplatin; D036104:Receptor, EphA2; D002945:Cisplatin
keywords: EphA2 receptor; Lipoplatin; combination therapy; liposomal nanoparticles; malignant pleural mesothelioma; non-small cell lung cancer